Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TGTX Stock Forecast 2026-2027
$40.16
Current Price
$6.15B
Market Cap
Buy 7
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to TGTX Price Targets
+74.3%
To High Target of $70.00
+24.5%
To Median Target of $50.00
-57.7%
To Low Target of $17.00
TGTX Price Momentum
+9.6%
1 Week Change
-6.3%
1 Month Change
+0.8%
1 Year Change
+34.7%
Year-to-Date Change
-10.1%
From 52W High of $44.65
+58.9%
From 52W Low of $25.28
📊 TOP ANALYST CALLS
Did TGTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if TG Therapeutics is one of their latest high-conviction picks.
Latest TGTX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, TGTX has a bullish consensus with a median price target of $50.00 (ranging from $17.00 to $70.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $40.16, the median forecast implies a 24.5% upside. This outlook is supported by 7 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Emily Bodnar at HC Wainwright & Co., projecting a 74.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TGTX Analyst Ratings
7
Buy
1
Hold
1
Sell
TGTX Price Target Range
Low
$17.00
Average
$50.00
High
$70.00
Current: $40.16
Latest TGTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TGTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 27, 2026 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $70.00 |
| May 6, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 2, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Jan 15, 2026 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Nov 3, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Oct 6, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Assumes | $60.00 |
| Sep 17, 2025 | B. Riley Securities | Buy | Maintains | $N/A | |
| Mar 4, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 15, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 25, 2024 | JP Morgan | Overweight | Maintains | $N/A | |
| Nov 5, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 5, 2024 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Oct 29, 2024 | TD Cowen | Buy | Initiates | $N/A | |
| Sep 18, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 7, 2024 | B. Riley Securities | Buy | Maintains | $N/A | |
| Aug 7, 2024 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Aug 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 2, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 2, 2024 | Ladenburg Thalmann | Buy | Maintains | $N/A | |
| Apr 18, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
TG Therapeutics, Inc. (TGTX) Competitors
The following stocks are similar to TG Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TGTX
TG Therapeutics
mkt cap
6.15B
TG Therapeutics, Inc. (TGTX) Financial Data
TG Therapeutics, Inc. has a market capitalization of $6.15B with a P/E ratio of 14.0x. The company generates $700.35M in trailing twelve-month revenue with a 66.0% profit margin.
Revenue growth is +69.6% quarter-over-quarter, while maintaining an operating margin of +17.0% and return on equity of +112.6%.
Valuation Metrics
Market Cap
$6.15B
Enterprise Value
$5.93B
P/E Ratio
14.0x
PEG Ratio
0.0x
Price/Sales
8.8x
Growth & Margins
Revenue Growth (YoY)
+69.6%
Gross Margin
+83.6%
Operating Margin
+17.0%
Net Margin
+66.0%
EPS Growth
+290.9%
Financial Health
Cash/Price Ratio
+9.0%
Current Ratio
5.8x
Debt/Equity
129.2x
ROE
+112.6%
ROA
+8.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
TG Therapeutics, Inc. (TGTX) Business Model
About TG Therapeutics, Inc.
What They Do
Develops therapies for B-cell mediated diseases.
Business Model
TG Therapeutics generates revenue primarily through the sales of its commercial product BRIUMVI, an anti-CD20 monoclonal antibody for multiple sclerosis patients. The company also has a diverse pipeline targeting B-cell malignancies and autoimmune disorders, indicating potential future revenue streams as these products progress through clinical development.
Additional Information
Founded in 1993 and based in Morrisville, North Carolina, TG Therapeutics is positioned in the health sector, focusing on immunology and oncology. The company's innovative approach to treating complex B-cell driven conditions highlights its commitment to addressing unmet medical needs in these areas.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
374
CEO
Mr. Michael S. Weiss Esq., J.D.
Country
United States
IPO Year
2010
Website
www.tgtherapeutics.comTG Therapeutics, Inc. (TGTX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 05, 2026
By Zacks Equity Research
Realtime BLOG
TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi
TG Therapeutics jumps 9.5% after phase I data show that subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated.
Jun 04, 2026
By Zacks Equity Research
Analyst Blog
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion regimen for relapsing MS patients.
May 28, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
TG Therapeutics (TGTX) reported earnings 30 days ago. Investors should monitor upcoming developments and market reactions for insights on the stock's future performance.
Why It Matters
TG Therapeutics' recent earnings report can indicate its financial health and future growth potential, influencing stock performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
TG Therapeutics stock rose after the company reported that an under-the-skin injection of Briumvi showed safety comparable to the intravenous version.
Why It Matters
TG Therapeutics' stock surge indicates positive investor sentiment and confidence in Briumvi's safety profile, potentially boosting market interest and future sales prospects.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
TG Therapeutics Inc (NASDAQ:TGTX) shares rose following positive early-stage clinical trial data for a new formulation of its multiple sclerosis drug, BRIUMVI.
Why It Matters
Positive early-stage trial results for BRIUMVI could indicate potential for future revenue growth, enhancing TG Therapeutics' market position and attracting investor interest.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
TG Therapeutics CEO Michael S. Weiss will participate in the Goldman Sachs 47th Annual Healthcare Conference in Miami Beach, FL, from June 8-10, 2026.
Why It Matters
Michael S. Weiss's participation in a major healthcare conference can signal potential insights into TG Therapeutics' strategy or pipeline, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BRIUMVI's quarterly subcutaneous dosing regimen is in a fully enrolled Phase 3 trial, with top-line data anticipated by late 2026 or early 2027.
Why It Matters
The progress of BRIUMVI's Phase 3 trial and potential for a quarterly dosing regimen could influence market perception and stock performance, impacting investor sentiment and valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
TG Therapeutics' stock rose 9.5% following Phase I data indicating that subcutaneous Briumvi had over 60% bioavailability and sustained drug exposure, with good tolerance.
Why It Matters
The 9.5% jump in TG Therapeutics reflects strong investor confidence in Briumvi's efficacy and safety, potentially increasing its market value and future revenue prospects.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About TGTX Stock
What is TG Therapeutics, Inc.'s (TGTX) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, TG Therapeutics, Inc. (TGTX) has a median price target of $50.00. The highest price target is $70.00 and the lowest is $17.00.
Is TGTX stock a good investment in 2026?
According to current analyst ratings, TGTX has 7 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $40.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TGTX stock?
Wall Street analysts predict TGTX stock could reach $50.00 in the next 12 months. This represents a 24.5% increase from the current price of $40.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is TG Therapeutics, Inc.'s business model?
TG Therapeutics generates revenue primarily through the sales of its commercial product BRIUMVI, an anti-CD20 monoclonal antibody for multiple sclerosis patients. The company also has a diverse pipeline targeting B-cell malignancies and autoimmune disorders, indicating potential future revenue streams as these products progress through clinical development.
What is the highest forecasted price for TGTX TG Therapeutics, Inc.?
The highest price target for TGTX is $70.00 from Emily Bodnar at HC Wainwright & Co., which represents a 74.3% increase from the current price of $40.16.
What is the lowest forecasted price for TGTX TG Therapeutics, Inc.?
The lowest price target for TGTX is $17.00 from at , which represents a -57.7% decrease from the current price of $40.16.
What is the overall TGTX consensus from analysts for TG Therapeutics, Inc.?
The overall analyst consensus for TGTX is bullish. Out of 3 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $50.00.
How accurate are TGTX stock price projections?
Stock price projections, including those for TG Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 5:01 PM UTC